Skip to content

Evaluation of the Performance of AIR OPTIX® COLORS

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01338402
Enrollment
47
Registered
2011-04-19
Start date
2011-04-30
Completion date
2012-03-31
Last updated
2014-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Brief summary

The purpose of this study was to assess the ocular response to and performance of the cosmetically printed silicone hydrogel contact lens AIR OPTIX® COLORS compared to FRESHLOOK® COLORBLENDS.

Detailed description

The study was conducted in two phases. Phase 1 was an adaptation phase where participants wore AIR OPTIX® AQUA contact lenses bilaterally (same product in both eyes) on a daily wear basis for 1 week. In Phase 2, participants wore AIR OPTIX® COLORS and FRESHLOOK® COLORBLENDS contact lenses contralaterally (different product in each eye) on a daily wear basis for 4 weeks.

Interventions

Silicone hydrogel contact lens

Silicone hydrogel contact lens with color

Hydrogel contact lens with color

Sponsors

University of Waterloo
CollaboratorOTHER
CIBA VISION
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
17 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Full legal capacity to volunteer; * Read and sign information and consent letter; * Willing and able to follow instructions and maintain the appointment schedule; * Ocular examination in the last two years; * Currently wears soft contact lenses on a daily wear basis; * Contact lens prescription between -1.50 diopters and -5.00 diopters; * Other protocol-defined inclusion criteria may apply.

Exclusion criteria

* Any ocular disease; * Any systemic condition that may affect a study outcome variable; * Any systemic or topical medications that may affect ocular health; * Known sensitivity to the diagnostic pharmaceuticals used in the study; * Unable to achieve an acceptable fit with the study lenses; * Anisometropia \>1.00 diopter or astigmatism \>0.75 diopter; * Use of lubricating/rewetting eye drops. * Other protocol-defined

Design outcomes

Primary

MeasureTime frame
Visual AcuityPhase 2: Up to Week 4
Corneal StainingPhase 2: Up to Week 4
Conjunctival StainingPhase 2: Up to Week 4
Surface Regularity Index (SRI)Up to Phase 2, Week 4
Surface Asymmetry Index (SAI)Up to Phase 2, Week 4
Subjective ratingsPhase 2: Up to Week 4

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026